BRPI0921263A2 - Anticorpos antir-receptor de tgf-beta ll - Google Patents

Anticorpos antir-receptor de tgf-beta ll

Info

Publication number: BRPI0921263A2
Authority: BR; Brazil
Prior art keywords: tgf; beta; receptor antibodies; antibodies; receptor
Prior art date: 2008-11-07

Application number

BRPI0921263-9A

Other languages

English (en)

Inventor

Yan Wu

Original Assignee

Imclone Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-11-07

Filing date

2009-10-29

Publication date

2015-08-04

2009-10-29 Application filed by Imclone Llc filed Critical Imclone Llc

2015-08-04 Publication of BRPI0921263A2 publication Critical patent/BRPI0921263A2/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BRPI0921263-9A 2008-11-07 2009-10-29 Anticorpos antir-receptor de tgf-beta ll BRPI0921263A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US19869708P	2008-11-07	2008-11-07
US17036909P	2009-04-17	2009-04-17
PCT/US2009/062450 WO2010053814A1 (en)	2008-11-07	2009-10-29	Anti-tgf-beta receptor ii antibodies

Publications (1)

Publication Number	Publication Date
BRPI0921263A2 true BRPI0921263A2 (pt)	2015-08-04

Family

ID=41508691

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0921263-9A BRPI0921263A2 (pt)	2008-11-07	2009-10-29	Anticorpos antir-receptor de tgf-beta ll

Country Status (19)

Country	Link
US (2)	US8147834B2 (pt)
EP (1)	EP2356152A1 (pt)
JP (1)	JP5667067B2 (pt)
KR (1)	KR101283856B1 (pt)
CN (1)	CN102209727B (pt)
AR (1)	AR073909A1 (pt)
AU (1)	AU2009311375B2 (pt)
BR (1)	BRPI0921263A2 (pt)
CA (1)	CA2742961C (pt)
EA (1)	EA025169B1 (pt)
IL (1)	IL211842A (pt)
JO (1)	JO3096B1 (pt)
MX (1)	MX2011004871A (pt)
NZ (1)	NZ591943A (pt)
PA (1)	PA8846101A1 (pt)
SG (1)	SG10201401280TA (pt)
TW (1)	TWI384998B (pt)
WO (1)	WO2010053814A1 (pt)
ZA (1)	ZA201103178B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG191762A1 (en)	2011-01-06	2013-08-30	Glaxo Group Ltd	Ligands that bind tgf-beta receptor ii
AR086044A1 (es)	2011-05-12	2013-11-13	Imclone Llc	Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
JP7170394B2 (ja)	2015-01-31	2022-11-14	ザトラスティーズオブザユニバーシティオブペンシルバニア	治療用分子のｔ細胞送達のための組成物および方法
TWI772275B (zh) *	2015-11-03	2022-08-01	美商健生生物科技公司	特異性結合pd-1、tim-3或pd-1與tim-3之抗體及其用途
SG11201807176XA (en)	2016-03-11	2018-09-27	Scholar Rock Inc	TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
AR109770A1 (es)	2016-10-18	2019-01-23	Lilly Co Eli	ANTICUERPOS DEL RECEPTOR II DE TGF-b
CN106884005A (zh) *	2017-01-19	2017-06-23	樊克兴	一种结直肠癌抗原特异性t细胞的制备方法
TW201922782A (zh)	2017-10-24	2019-06-16	美商麥珍塔治療學股份有限公司	去除cd117+細胞之組合物及方法
WO2019084053A1 (en) *	2017-10-24	2019-05-02	Magenta Therapeutics, Inc.	COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
CN111372608B (zh)	2017-10-24	2024-07-02	克里斯珀医疗股份公司	用于耗尽cd117+细胞的组合物和方法
CN107973853B (zh) *	2017-12-12	2021-04-30	山西农业大学	一种利用特征多肽制备Smad2蛋白特异性抗体的方法及其应用
EP4081306A1 (en) *	2019-12-24	2022-11-02	Merus N.V.	Tgf-beta-rii binding proteins
KR102314157B1 (ko) *	2020-01-10	2021-10-19	주식회사 뉴클릭스바이오	TGF-β 수용체에 특이적으로 결합하는 항체 및 이의 이용방법
WO2023198194A1 (en) *	2022-04-15	2023-10-19	Biocytogen Pharmaceuticals (Beijing) Co., Ltd.	Anti-cd40 antibodies and uses thereof
CN116178567A (zh) *	2022-10-28	2023-05-30	四川大学华西医院	一种靶向TGFβRII的嵌合抗原受体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
EP1149908A1 (en)	1991-10-31	2001-10-31	Whitehead Institute For Biomedical Research	TGF-beta type receptor cDNAs and uses thereof
JP2001206899A (ja) *	1999-11-18	2001-07-31	Japan Tobacco Inc	ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
JP2004121001A (ja) *	2002-08-07	2004-04-22	Japan Tobacco Inc	ＴＧＦ−βＩＩ型受容体に対する高親和性モノクローナル抗体
WO2007088651A1 (ja) *	2006-02-01	2007-08-09	The University Of Tokyo	ＴＧＦ－βシグナル阻害剤と抗腫瘍剤の組み合せ使用

2009
- 2009-10-18 JO JOP/2009/0382A patent/JO3096B1/ar active
- 2009-10-19 TW TW098135300A patent/TWI384998B/zh not_active IP Right Cessation
- 2009-10-19 AR ARP090104017A patent/AR073909A1/es unknown
- 2009-10-19 PA PA20098846101A patent/PA8846101A1/es unknown
- 2009-10-29 WO PCT/US2009/062450 patent/WO2010053814A1/en active Application Filing
- 2009-10-29 SG SG10201401280TA patent/SG10201401280TA/en unknown
- 2009-10-29 KR KR1020117010399A patent/KR101283856B1/ko not_active IP Right Cessation
- 2009-10-29 AU AU2009311375A patent/AU2009311375B2/en not_active Ceased
- 2009-10-29 CA CA2742961A patent/CA2742961C/en not_active Expired - Fee Related
- 2009-10-29 BR BRPI0921263-9A patent/BRPI0921263A2/pt not_active IP Right Cessation
- 2009-10-29 EP EP09745224A patent/EP2356152A1/en not_active Withdrawn
- 2009-10-29 CN CN200980144391.1A patent/CN102209727B/zh not_active Expired - Fee Related
- 2009-10-29 NZ NZ591943A patent/NZ591943A/xx not_active IP Right Cessation
- 2009-10-29 US US12/608,034 patent/US8147834B2/en not_active Expired - Fee Related
- 2009-10-29 MX MX2011004871A patent/MX2011004871A/es active IP Right Grant
- 2009-10-29 JP JP2011534731A patent/JP5667067B2/ja not_active Expired - Fee Related
- 2009-10-29 EA EA201170659A patent/EA025169B1/ru not_active IP Right Cessation
2011
- 2011-03-21 IL IL211842A patent/IL211842A/en not_active IP Right Cessation
- 2011-04-29 ZA ZA2011/03178A patent/ZA201103178B/en unknown
2012
- 2012-02-20 US US13/400,308 patent/US20120177666A1/en not_active Abandoned

Also Published As

Publication number	Publication date
TWI384998B (zh)	2013-02-11
US8147834B2 (en)	2012-04-03
US20100119516A1 (en)	2010-05-13
AU2009311375A1 (en)	2010-05-14
CN102209727B (zh)	2014-07-30
JO3096B1 (ar)	2017-03-15
KR101283856B1 (ko)	2013-07-15
JP5667067B2 (ja)	2015-02-12
JP2012508170A (ja)	2012-04-05
AR073909A1 (es)	2010-12-09
AU2009311375B2 (en)	2014-07-31
CN102209727A (zh)	2011-10-05
TW201026326A (en)	2010-07-16
KR20110067155A (ko)	2011-06-21
ZA201103178B (en)	2012-10-31
WO2010053814A1 (en)	2010-05-14
EA201170659A1 (ru)	2011-10-31
CA2742961A1 (en)	2010-05-14
CA2742961C (en)	2016-08-30
PA8846101A1 (es)	2010-06-28
IL211842A0 (en)	2011-06-30
IL211842A (en)	2016-09-29
NZ591943A (en)	2012-11-30
US20120177666A1 (en)	2012-07-12
EA025169B1 (ru)	2016-11-30
EP2356152A1 (en)	2011-08-17
SG10201401280TA (en)	2014-05-29
MX2011004871A (es)	2011-07-13

Legal Events

Date	Code	Title	Description
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-05-08	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2019-08-27	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 10A ANUIDADE.
2019-12-17	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2538 DE 27-08-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
CY2019004I1 (el)	2019-11-27	Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0921263A2 (pt)	2015-08-04	Anticorpos antir-receptor de tgf-beta ll
HK1222397A1 (zh)	2017-06-30	診斷抗體測定
BRPI0820819A2 (pt)	2015-06-16	Formulação de anticorpos
BRPI0906877A2 (pt)	2015-07-28	Anticorpos anti-trkb aperfeiçoados
BRPI0922730A2 (pt)	2018-11-06	formulação de anticorpo
BRPI0920648A2 (pt)	2015-08-25	Combinações pesticidas contendo sulfoxaflor
BRPI0907237A2 (pt)	2015-07-14	Anticorpo anti-cldn6
BRPI0814252A2 (pt)	2015-04-14	Formulações de anticorpo
BRPI0814003A2 (pt)	2015-02-03	Formulações de anticorpo
BRPI0922800A2 (pt)	2015-12-22	anticorpos c-met
BRPI0815567A2 (pt)	2015-02-18	Anticorpos híbridos antialfa v-integrina projetados
BRPI0909644A2 (pt)	2015-09-22	dispositivo de foto-epilação
BRPI0917888A2 (pt)	2014-02-25	Formulação de anticorpo líquida estável
DE602008006646D1 (de)	2011-06-16	Fahrzeugstrukturelement
BRPI0910229A2 (pt)	2015-09-01	Tetramatos de 4';4'-dioxaspiro espirociclicamente substituídos
UY3847Q (es)	2009-07-17	Lata
BRPI0807991A2 (pt)	2014-06-17	Anticorpos anti-il-23r elaborados.
BRPI0913961A2 (pt)	2015-10-20	dispositivo de amortecimento
DE112008002581A5 (de)	2010-06-24	Antriebsstrang
BRPI0817427A2 (pt)	2015-06-16	Anticorpo anti-bst2
BRPI0909633A2 (pt)	2015-09-22	anticorpos anti-tyrp1
DE112007003038A5 (de)	2009-09-17	Antriebsstrang
BRPI0819765A2 (pt)	2015-05-05	Conjugados de anticorpos anti-rg-1
BRPI0912769A2 (pt)	2015-10-13	anticorpos anti-pirb